Catalyst Funds Management’s Vaxcyte PCVX Stock Holding History

Catalyst Funds Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-18,400	Closed	-$1.51M	–	558
2024 Q4	$1.51M	Buy	18,400 +300	+2%	+$29.8K	0.37%	56
2024 Q3	$2.07M	Buy	+18,100	New	+$1.63M	0.45%	33
2024 Q2	–	Sell	-400	Closed	-$27.3K	–	1490
2024 Q1	$27.3K	Buy	+400	New	+$27.7K	0.01%	690

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Catalyst Funds Management's PCVX Position: Q1 2025 in Review

Catalyst Funds Management sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 18,400 shares — an estimated $1.51M sold.

Catalyst Funds Management first reported a position in PCVX in Q1 2024 and held it in 3 quarters. The position peaked at $2.07M in Q3 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

Catalyst Funds Management reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
Catalyst Funds Management sold 18,400 Vaxcyte shares in Q1 2025, an estimated $1.51M.
Catalyst Funds Management first reported a position in Vaxcyte in Q1 2024 and held it in 3 quarters.
Catalyst Funds Management's Vaxcyte position peaked at $2.07M in Q3 2024.
315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Catalyst Funds Management's 13F filing for Q1 2025, filed 14 May 2025.